Skip to main content
. 2018 May 11;9(36):24548–24560. doi: 10.18632/oncotarget.24647

Figure 2. The efficacy evaluation of apatinib in the phase II clinical trial in patients with advanced metastatic gastric cancer.

Figure 2

(A) Kaplan-Meier estimates of progression-free survival (PFS). (B) Kaplan-Meier estimates of overall survival (OS). BID, twice a day; QD, once a day. (Cited from: Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013; 31: 3219-25. doi: 10.1200/JCO.2013.48.8585.)